At the annual Neuroscience Innovations Conference in San Francisco, Medtronic executives told more than 400 industry leaders that the company has significant firepower to pursue multiple acquisitions over the next 12 to 18 months. Chief Financial Officer Karen Parkhill highlighted that Medtronic’s balance sheet carries approximately $16 billion in available liquidity, including undrawn credit lines and cash reserves, and pointed to a net debt leverage ratio of 2.8x as support for further strategic M&A. Executives identified robotics-assisted surgery and cardiovascular diagnostics as priority areas, recalling that since 2019 the company has deployed over $8 billion acquiring Affera, Digital Surgery and Aptus Endosystems. Management said it is targeting tuck-in deals in the $100 million to $1 billion range, as well as potential marquee transactions in adjacent high-growth segments.

Medtronic announced a partnership with Precision Neuroscience to integrate the latter’s Layer 7™ cortical interface into the StealthStation™ surgical navigation platform. The collaboration will co-develop an end-to-end neurosurgical solution designed to overlay high-resolution, real-time functional maps onto 3D anatomical images. According to Michael Mager, CEO of Precision Neuroscience, the joint system aims to reduce intraoperative decision time by up to 20% and improve electrode placement accuracy by a factor of five. Medtronic’s Neuroscience leadership said the integrated platform is slated for clinical trials in mid-2027, with a global commercial launch targeted for early 2029, reinforcing the company’s push into advanced neuromodulation and adaptive therapies.